Taro Pharmaceutical names Uday Baldota CEO, announces board changes
Taro Pharmaceutical announced the appointment of Uday Baldota as CEO and as a nominee to Taro's board. He is expected to begin his role as CEO on or about April 1, 2017, and will focus solely on the Taro business. Baldota currently serves as the EVP & CFO of Sun Pharmaceutical Industries, and is a member of Sun's global management team. Certain terms of Baldota's appointment as CEO and nomination to the Taro Board are subject to the approval of Taro's shareholders, which will be voted on at the annual shareholder meeting in December. In addition to Baldota's nomination to the Taro board, Abhay Gandhi, Kal Sundaram's successor as the CEO of Sun North America, is also being nominated to the board and is expected to be proposed as Vice Chairman after the 2016 shareholder meeting. Due to Taro's regular rotation principle for external directors, Dan Biran and Ilana Avidov-Mor will be retiring from Taro's board. Two candidates have been nominated to fill these vacancies -- Linda Benshoshan and Elli Streit.